Biodistribution of cyclosporin encapsulated in liposomes modified with bioadhesive polymer

Journal of Pharmacy and Pharmacology

Volumn 49, Issue 7, 1997, Pages 661-668

  Yoshikawa, Yukako ^a   Miyazaki, Masaya ^a   Houjou, Takeshi ^a   Komuta, Yutaka ^a   Yoshikawa, Hiroshi ^b   Takada, Kanji ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOMER; CYCLOSPORIN; LIPOSOME; POLYACRYLIC ACID; POLYMER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; ENCAPSULATION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PHARMACODYNAMICS; PLASMA CLEARANCE; RAT; TISSUE DISTRIBUTION;

EID: 0030841096     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.1997.tb06089.x     Document Type: Article

References (36)

1. Awni, W. M. (1992) Pharmacodynamic monitoring of cyclosporin. Clin. Pharmacokinet. 23: 428-448
2. Aziz, S., Bieber, C. P., Reitz, B. A., Bieber, M. M., Oyer, P. E., Hoyt, G., Stinson, E. B. (1981) Preparation and efficacy of cyclosporin-A liposomes for prolongation of cardiac allograft survival. Transplant. Proc. 13: 410-411
3. Baumann, G., Zenke, G., Wenger, R., Hiestand, P., Quesniaux, V., Andersen, E., Schreier, M. H. (1992) Molecular mechanism of immunosuppression. J. Autoimmunity 5: 67-72
4. Bergers, J. J., ten Hagen, T. L. M., van Etten, E. W. M., Bakker-Woudenberg, I. A. J. M. (1995) Liposomes as delivery systems in the prevention and treatment of infectious diseases. Pharm. World Sci. 17: 1-11
5. Dean, T. (1993) Liposomes in allergy and immunology. Clin. Exp. Allerg. 23: 557-563
6. Dong, C., Rogers, J. A. (1993) Acacia-gelatin microencapsulated liposomes: preparation, stability, and release of acetylsalicylic acid. Pharm. Res. 10: 141-146
7. Fahr, A. (1993) Cyclosporin clinical pharmacokinetics. Clin. Pharmacokinet. 24: 472-495
8. Fahr, A., Holz, M., Fricker, G. (1995) Liposomal formulation of cyclosporin: influence of lipid type and dose on pharmacokinetics. Pharm. Res. 12: 1189-1198
9. Gorecki, D., Jakobisiak, M., Kruszewski, A., Lasek, W. (1991) Evidence that liposome incorporation of cyclosporine reduces its toxicity and potentiates its ability to prolong survival of cardiac allografts in mice. Transplantation 52: 766-769
10. Gruber, S. A., Venkataram, S., Canafax, D. M., Cipolle, R. J., Bowers, L., Elsberry, D., McGuiggan, M., Hynes, P. E., Ritz, J. A., Gould, F. H., Matas, A., Hrushesky, W. H. M., Rahman, Y. E. (1989) Liposomal formulation eliminates acute toxicity and pump incompatibility of parenteral cyclosporine. Pharm. Res. 6: 601-607
11. Harashima, H., Hirai, N., Kiwada, H. (1995) Kinetic modelling of liposome degradation in peritoneal macrophages. Biopharm. Drug Dispos. 16: 113-123
12. Kahan, D. D. (1989) Drug therapy. Cyclosporin. N. Engl. J. Med. 321: 1725-1738
13. Katayama, N., Houjou, T., Takada, K. (1994) Lymphatic absorption of cyclosporin from the abdominal cavity. Int. J. Pharm. 110: 155-160
14. Katayama, N., Tanaka, R., Ohno, Y., Ueda, C., Houjou, T., Takada, K. (1995) Implantable slow release cyclosporin A delivery system to thoracic lymph duct. Int. J. Pharm. 115: 87-93
15. Ko, S., Nakajima, Y., Kanehiro, H., Yoshimura, A., Nakano, H. (1994) The pharmacokinetic benefits of newly developed liposome-incorporated FK506. Transplantation 58: 1142-1144
16. Ko, S., Nakajima, Y., Kanehiro, H., Horikawa, M., Yoshimura, A., Taki, J., Aomatsu, Y., Kin, T., Yagura, K., Nakano, H. (1995) The enhanced immunosuppressive efficacy of newly developed liposomal FK506 in canine liver transplantation. Transplantation 59: 1384-1388
17. Kronke, M., Leonard, W. J., Depper, J. M., Arya, S. K., Wong-Staal, F., Gallo, R. C., Waldmann, T. A., Greene, W. C. (1984) Cyclosporin inhibits T-cell growth factor gene-expression at the level of mRNA transcription. Proc. Natl Acad. Sci. USA 81: 5214-5218
18. Lee, M.-J., Straubinger, R. M., Jusko, W. S. (1995) Physicochemical, pharmacokinetic and pharmacodynamic evaluation of liposomal tacrolimus (FK506) in rats. Pharm. Res. 12: 1055-1059
19. Merion, R. M. (1985) Measurements of reticuloendothelial system phagocytic activity in the rat after treatment with silica, liposomes, and cyclosporine. Transplantation 40: 86-90
20. Moghimi, S. M., Davis, S. S. (1994) Innovations in avoiding particle clearance from blood by Kupffer cells: cause for reflection. Crit. Rev. Ther. Drug Carrier Sys. 11: 31-59
21. Mori, A., Kennel, S. J., Huang, L. (1993) Immunotargeting of liposomes containing lipophilic antitumor prodrugs. Pharm. Res. 10: 507-514
22. Nakaji, K., Nakata, T., Yasumura, T., Ohmori, Y., Oka, T., Takada, K., Muranishi, S. (1988) Prolongation of rat renal allograft survival by injection of a small dose of cyclosporin into the thoracic duct. Transplant. Proc. 20: 298-300
23. Pabst, R., Binns, R. M. (1989) Heterogeneity of lymphocytes homing physiology. Several mechanisms operate in the control of migration to lymphoid and non-lymphoid organs in vivo. Immunol. Rev. 108: 83-109
24. Sackstein, R. (1993) Physiologic migration of lymphocytes to lymph nodes following bone marrow transplantation: role in immune recovery. Semin. Oncol. 20: 34-39
25. Shibata, N., Minouhi, T., Hayashi, Y., Ono, T., Shimokawa, H. (1987) Quantitative determination of cyclosporin in whole blood and plasma by high performance liquid chromatography. Res. Commun. Chem. Pathol. Pharmacol. 57: 261-271
26. Sigal, N. H., Dumont, F. J. (1992) Cyclosporin, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu. Rev. Immunol. 10: 519-560
27. Takada, K., Shibata, N., Yoshimura, H., Yoshikawa, H., Muranishi, S. (1985) High-performance liquid chromatographic determination of cyclosporin in body fluids. Res. Commun. Chem. Pathol. Pharmacol. 48: 369-380
28. Takada, K., Yoshimura, H., Yoshikawa, H., Muranishi, S., Yasumura, T., Oka, T. (1986) Enhanced selective lymphatic delivery of cyclosporin by solubilizer and intensified immunosuppressive activity against mice skin allograft. Pharm. Res. 3: 48-51
29. Takada, K., Furuya, Y., Yoshikawa, H., Muranishi, S. (1988) Biological and pharmaceutical factors affecting the absorption and lymphatic delivery of cyclosporin from the gastrointestinal tract. J. Pharmacobiodyn. 11: 80-87
30. Takada, K., Oh-hashi, M., Furuya, Y., Yoshikawa, H., Muranishi, S. (1989) Enteric solid dispersion of cyclosporin having potential to deliver cyclosporin into lymphatics. Chem. Pharm. Bull. 37: 471-474
31. Thomson, A. W. (1989) Sandimmun: Mode of Action and Clinical Application. Kluwer, Dordrecht
32. Tocci, M. J., Matkovich, K. A., Collier, K. A., Kwok, P., Dumont, F., Lin, S., Degudicibus, S., Siekierka, J. J., Chin, J., Hutchinson, N. I. (1989) The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J. Immunol 143: 718-726
33. Vadiei, K., Lopez-Berestein, G., Perez-Soler, R., Luke, D. R. (1989) In vitro evaluation of liposomal cyclosporine. Int. J. Pharm. 57: 133-138
34. Vadiei, K., Lopez-Berestein, G., Perez-Soler, R., Luke, D. R. (1991) Tissue distribution and in vivo immunosuppressive activity of liposomal cyclosporine. Drug Metab. Dispos. 19: 1147-1151
35. Venkataram, S., Awni, W. M., Jordan, K., Rahman, Y. E. (1990) Pharmacokinetics of two alternative dosage forms for cyclosporine: liposomes and intralipid. J. Pharm. Sci. 79: 216-219
36. Yerushalmi, N., Margalit, R. (1994) Bioadhesive, collagen-modified liposomes: molecular and cellular level studies on the kinetics of drug release and on binding to cell monolayers. Biochim. Biophys. Acta 1189: 13-20